AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMMX
  4. [Form 4] Immix Biopharma, Inc. Insider Trading Activity

[Form 4] Immix Biopharma, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Immix Biopharma, Inc. (IMMX) filed a Form 4 on 23-Jun-2025 disclosing an equity award to insider Gabriel S. Morris, who serves as Director and Chief Financial Officer.

On 20-Jun-2025 Mr. Morris received 340,000 stock options with a $2.24 exercise price. The options vest in 48 equal monthly instalments and expire on 20-Jun-2035, signalling a long-term incentive structure tied to continued service.

Post-grant, Mr. Morris reports beneficial ownership of:

  • 288,059 common shares held directly.
  • 270,844 common shares held indirectly through Alwaysraise LLC.
  • 24,141 common shares held indirectly through Alwaysraise Ventures I LP.
  • 340,000 option shares newly awarded.
This totals 582,,,,,,ционной share options and 582,,,?直接持有 shares.

The filing shows no open-market purchases or sales; the transaction code “A” denotes an award. While the option grant introduces potential future dilution, it also aligns executive incentives with shareholder value creation over a ten-year horizon.

Immix Biopharma, Inc. (IMMX) ha presentato un Modulo 4 il 23 giugno 2025, rivelando un premio azionario all'interno dell'azienda per Gabriel S. Morris, che ricopre i ruoli di Direttore e Direttore Finanziario.

Il 20 giugno 2025, il Sig. Morris ha ricevuto 340.000 opzioni su azioni con un prezzo di esercizio di 2,24 $. Le opzioni maturano in 48 rate mensili uguali e scadono il 20 giugno 2035, indicando una struttura di incentivi a lungo termine legata alla continuità del servizio.

Dopo l'assegnazione, il Sig. Morris dichiara la proprietà effettiva di:

  • 288.059 azioni ordinarie detenute direttamente.
  • 270.844 azioni ordinarie detenute indirettamente tramite Alwaysraise LLC.
  • 24.141 azioni ordinarie detenute indirettamente tramite Alwaysraise Ventures I LP.
  • 340.000 azioni opzione appena assegnate.
Il totale ammonta a circa 923.044 azioni ordinarie e opzioni.

Il documento non mostra acquisti o vendite sul mercato aperto; il codice della transazione “A” indica un premio. Sebbene la concessione delle opzioni possa comportare una diluizione futura, essa allinea anche gli incentivi del management con la creazione di valore per gli azionisti su un orizzonte decennale.

Immix Biopharma, Inc. (IMMX) presentó un Formulario 4 el 23 de junio de 2025, revelando una concesión de acciones a un insider, Gabriel S. Morris, quien se desempe?a como Director y Director Financiero.

El 20 de junio de 2025, el Sr. Morris recibió 340,000 opciones sobre acciones con un precio de ejercicio de $2.24. Las opciones se consolidan en 48 cuotas mensuales iguales y vencen el 20 de junio de 2035, indicando una estructura de incentivos a largo plazo vinculada a la continuidad del servicio.

Después de la concesión, el Sr. Morris reporta la propiedad beneficiaria de:

  • 288,059 acciones ordinarias en propiedad directa.
  • 270,844 acciones ordinarias en propiedad indirecta a través de Alwaysraise LLC.
  • 24,141 acciones ordinarias en propiedad indirecta a través de Alwaysraise Ventures I LP.
  • 340,000 opciones sobre acciones recién otorgadas.
Esto suma un total de aproximadamente 923,044 acciones ordinarias y opciones.

La presentación no muestra compras o ventas en el mercado abierto; el código de transacción “A” indica una concesión. Aunque la concesión de opciones introduce una posible dilución futura, también alinea los incentivos ejecutivos con la creación de valor para los accionistas en un horizonte de diez a?os.

Immix Biopharma, Inc. (IMMX)? 2025? 6? 23? ??? ???? S. ???(Gabriel S. Morris)?? ?? ??? ???? Form 4? ??????. ???? ?? ? ???????(CFO)???.

2025? 6? 20?, ??? ?? 340,000?? ????? ??? 2.24??? ?????. ? ??? 48??? ?? ?? ??? ??? ??? ????, ???? 2035? 6? 20?? ?? ???? ??? ?????.

?? ?? ?, ??? ?? ??? ?? ?? ??? ??????:

  • ?? ?? ?? 288,059? ???
  • Alwaysraise LLC? ?? ?? ?? ?? 270,844? ???
  • Alwaysraise Ventures I LP? ?? ?? ?? ?? 24,141? ???
  • ?? ???? 340,000? ??
? ? 923,044?? ??? ? ??? ?????.

?? ???? ?? ????? ?? ??? ???, ?? ?? “A”? ??? ?????. ?? ??? ???? ?? ?? ??? ?????, ???? ????? ?? ?? ??? 10?? ????? ??? ???.

Immix Biopharma, Inc. (IMMX) a déposé un formulaire 4 le 23 juin 2025, révélant une attribution d'actions à l'initié Gabriel S. Morris, qui occupe les postes de directeur et de directeur financier.

Le 20 juin 2025, M. Morris a re?u 340 000 options d'achat d'actions avec un prix d'exercice de 2,24 $. Les options sont acquises par tranches mensuelles égales sur 48 mois et expirent le 20 juin 2035, indiquant une structure d'incitation à long terme liée à la continuité du service.

Après cette attribution, M. Morris déclare la propriété bénéficiaire de :

  • 288 059 actions ordinaires détenues directement.
  • 270 844 actions ordinaires détenues indirectement via Alwaysraise LLC.
  • 24 141 actions ordinaires détenues indirectement via Alwaysraise Ventures I LP.
  • 340 000 options d'achat d'actions nouvellement attribuées.
Ce qui totalise environ 923 044 actions ordinaires et options.

Le dép?t ne montre aucune transaction sur le marché ouvert ; le code de transaction ? A ? indique une attribution. Bien que l'octroi d'options puisse entra?ner une dilution potentielle future, il aligne également les incitations des dirigeants sur la création de valeur pour les actionnaires sur un horizon de dix ans.

Immix Biopharma, Inc. (IMMX) reichte am 23. Juni 2025 ein Formular 4 ein, das eine Aktienzuteilung an den Insider Gabriel S. Morris offenlegt, der als Direktor und Chief Financial Officer t?tig ist.

Am 20. Juni 2025 erhielt Herr Morris 340.000 Aktienoptionen mit einem Ausübungspreis von 2,24 $. Die Optionen werden in 48 gleichen monatlichen Raten übertragen und laufen am 20. Juni 2035 ab, was eine langfristige Anreizstruktur im Zusammenhang mit fortgesetzter Dienstzeit signalisiert.

Nach der Zuteilung meldet Herr Morris den wirtschaftlichen Besitz von:

  • 288.059 Stammaktien, die direkt gehalten werden.
  • 270.844 Stammaktien, die indirekt über Alwaysraise LLC gehalten werden.
  • 24.141 Stammaktien, die indirekt über Alwaysraise Ventures I LP gehalten werden.
  • 340.000 neu gew?hrte Optionsaktien.
Dies ergibt insgesamt ca. 923.044 Stammaktien und Optionen.

Die Einreichung zeigt keine K?ufe oder Verk?ufe am offenen Markt; der Transaktionscode ?A“ steht für eine Zuteilung. Obwohl die Optionsgew?hrung eine potenzielle zukünftige Verw?sserung mit sich bringt, stimmt sie die Anreize der Führungskr?fte auch mit der Wertschaffung für die Aktion?re über einen Zeitraum von zehn Jahren ab.

Positive
  • Significant insider equity ownership of roughly 582 k shares aligns management incentives with shareholders.
Negative
  • Grant of 340,000 stock options adds potential future dilution and option overhang.

Insights

TL;DR: Routine option grant; strengthens retention, modest dilution; neutral governance impact.

The Form 4 documents a standard compensation action. A 340 k option package with four-year vesting is common for dual Director/CFO roles in micro-cap biotech. The long vesting horizon incentivises continuity and aligns Mr. Morris with equity performance. There is no evidence of opportunistic timing or 10b5-1 plan usage. Without information on total shares outstanding, dilution significance cannot be quantified, but the single-digit nature of the award relative to typical micro-cap floats suggests limited impact. Overall, governance implications are neutral.

TL;DR: Neutral for valuation; option strike near market, no cash outflow, small potential overhang.

This filing neither signals insider buying nor selling—merely compensation. The $2.24 strike likely approximates the 20-Jun-2025 market price, so the award is not immediately in-the-money. Investors should watch for cumulative option overhang but, on its own, 340 k options are unlikely to move the share-count needle materially. The insider’s 582 k share exposure (direct + indirect) reflects meaningful skin-in-the-game, a modest positive for alignment. Net impact to valuation models or near-term trading dynamics is negligible.

Immix Biopharma, Inc. (IMMX) ha presentato un Modulo 4 il 23 giugno 2025, rivelando un premio azionario all'interno dell'azienda per Gabriel S. Morris, che ricopre i ruoli di Direttore e Direttore Finanziario.

Il 20 giugno 2025, il Sig. Morris ha ricevuto 340.000 opzioni su azioni con un prezzo di esercizio di 2,24 $. Le opzioni maturano in 48 rate mensili uguali e scadono il 20 giugno 2035, indicando una struttura di incentivi a lungo termine legata alla continuità del servizio.

Dopo l'assegnazione, il Sig. Morris dichiara la proprietà effettiva di:

  • 288.059 azioni ordinarie detenute direttamente.
  • 270.844 azioni ordinarie detenute indirettamente tramite Alwaysraise LLC.
  • 24.141 azioni ordinarie detenute indirettamente tramite Alwaysraise Ventures I LP.
  • 340.000 azioni opzione appena assegnate.
Il totale ammonta a circa 923.044 azioni ordinarie e opzioni.

Il documento non mostra acquisti o vendite sul mercato aperto; il codice della transazione “A” indica un premio. Sebbene la concessione delle opzioni possa comportare una diluizione futura, essa allinea anche gli incentivi del management con la creazione di valore per gli azionisti su un orizzonte decennale.

Immix Biopharma, Inc. (IMMX) presentó un Formulario 4 el 23 de junio de 2025, revelando una concesión de acciones a un insider, Gabriel S. Morris, quien se desempe?a como Director y Director Financiero.

El 20 de junio de 2025, el Sr. Morris recibió 340,000 opciones sobre acciones con un precio de ejercicio de $2.24. Las opciones se consolidan en 48 cuotas mensuales iguales y vencen el 20 de junio de 2035, indicando una estructura de incentivos a largo plazo vinculada a la continuidad del servicio.

Después de la concesión, el Sr. Morris reporta la propiedad beneficiaria de:

  • 288,059 acciones ordinarias en propiedad directa.
  • 270,844 acciones ordinarias en propiedad indirecta a través de Alwaysraise LLC.
  • 24,141 acciones ordinarias en propiedad indirecta a través de Alwaysraise Ventures I LP.
  • 340,000 opciones sobre acciones recién otorgadas.
Esto suma un total de aproximadamente 923,044 acciones ordinarias y opciones.

La presentación no muestra compras o ventas en el mercado abierto; el código de transacción “A” indica una concesión. Aunque la concesión de opciones introduce una posible dilución futura, también alinea los incentivos ejecutivos con la creación de valor para los accionistas en un horizonte de diez a?os.

Immix Biopharma, Inc. (IMMX)? 2025? 6? 23? ??? ???? S. ???(Gabriel S. Morris)?? ?? ??? ???? Form 4? ??????. ???? ?? ? ???????(CFO)???.

2025? 6? 20?, ??? ?? 340,000?? ????? ??? 2.24??? ?????. ? ??? 48??? ?? ?? ??? ??? ??? ????, ???? 2035? 6? 20?? ?? ???? ??? ?????.

?? ?? ?, ??? ?? ??? ?? ?? ??? ??????:

  • ?? ?? ?? 288,059? ???
  • Alwaysraise LLC? ?? ?? ?? ?? 270,844? ???
  • Alwaysraise Ventures I LP? ?? ?? ?? ?? 24,141? ???
  • ?? ???? 340,000? ??
? ? 923,044?? ??? ? ??? ?????.

?? ???? ?? ????? ?? ??? ???, ?? ?? “A”? ??? ?????. ?? ??? ???? ?? ?? ??? ?????, ???? ????? ?? ?? ??? 10?? ????? ??? ???.

Immix Biopharma, Inc. (IMMX) a déposé un formulaire 4 le 23 juin 2025, révélant une attribution d'actions à l'initié Gabriel S. Morris, qui occupe les postes de directeur et de directeur financier.

Le 20 juin 2025, M. Morris a re?u 340 000 options d'achat d'actions avec un prix d'exercice de 2,24 $. Les options sont acquises par tranches mensuelles égales sur 48 mois et expirent le 20 juin 2035, indiquant une structure d'incitation à long terme liée à la continuité du service.

Après cette attribution, M. Morris déclare la propriété bénéficiaire de :

  • 288 059 actions ordinaires détenues directement.
  • 270 844 actions ordinaires détenues indirectement via Alwaysraise LLC.
  • 24 141 actions ordinaires détenues indirectement via Alwaysraise Ventures I LP.
  • 340 000 options d'achat d'actions nouvellement attribuées.
Ce qui totalise environ 923 044 actions ordinaires et options.

Le dép?t ne montre aucune transaction sur le marché ouvert ; le code de transaction ? A ? indique une attribution. Bien que l'octroi d'options puisse entra?ner une dilution potentielle future, il aligne également les incitations des dirigeants sur la création de valeur pour les actionnaires sur un horizon de dix ans.

Immix Biopharma, Inc. (IMMX) reichte am 23. Juni 2025 ein Formular 4 ein, das eine Aktienzuteilung an den Insider Gabriel S. Morris offenlegt, der als Direktor und Chief Financial Officer t?tig ist.

Am 20. Juni 2025 erhielt Herr Morris 340.000 Aktienoptionen mit einem Ausübungspreis von 2,24 $. Die Optionen werden in 48 gleichen monatlichen Raten übertragen und laufen am 20. Juni 2035 ab, was eine langfristige Anreizstruktur im Zusammenhang mit fortgesetzter Dienstzeit signalisiert.

Nach der Zuteilung meldet Herr Morris den wirtschaftlichen Besitz von:

  • 288.059 Stammaktien, die direkt gehalten werden.
  • 270.844 Stammaktien, die indirekt über Alwaysraise LLC gehalten werden.
  • 24.141 Stammaktien, die indirekt über Alwaysraise Ventures I LP gehalten werden.
  • 340.000 neu gew?hrte Optionsaktien.
Dies ergibt insgesamt ca. 923.044 Stammaktien und Optionen.

Die Einreichung zeigt keine K?ufe oder Verk?ufe am offenen Markt; der Transaktionscode ?A“ steht für eine Zuteilung. Obwohl die Optionsgew?hrung eine potenzielle zukünftige Verw?sserung mit sich bringt, stimmt sie die Anreize der Führungskr?fte auch mit der Wertschaffung für die Aktion?re über einen Zeitraum von zehn Jahren ab.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Morris Gabriel S
(Last) (First) (Middle)
C/O IMMIX BIOPHARMA, INC.
11400 WEST OLYMPIC BLVD., SUITE 200
(Street)
LOS ANGELES CA 90064
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Immix Biopharma, Inc. [ IMMX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CFO
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 288,059 D
Common Stock 270,844 I See footnote(1)
Common Stock 24,141 I See footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $2.24 06/20/2025 A 340,000 (3) 06/20/2035 Common Stock 340,000 $0.00 340,000 D
Explanation of Responses:
1. Gabriel Morris is the Managing Partner and Sole Member of Alwaysraise LLC ("Alwaysraise") and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Morris disclaims beneficial ownership of the securities reported herein as held by Alwaysraise, except to the extent of his pecuniary interest therein.
2. Gabriel Morris is the Managing Partner of Alwaysraise Ventures I Investments, LLC ("Alwaysraise Ventures"), the general partner of Alwaysraise Ventures I, LP. ("AVILP") and in such capacity has the right to vote and dispose of the securities held by such entity. Mr. Morris disclaims beneficial ownership of the securities reported herein as held by AVILP, except to the extent of his pecuniary interest therein.
3. The Stock Option will vest in forty-eight (48) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.
/s/ Gabriel Morris 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many stock options did IMMX CFO Gabriel S. Morris receive?

Mr. Morris was granted 340,000 stock options on 20-Jun-2025.

What is the exercise price of the new IMMX options?

The options carry a $2.24 per-share exercise price.

When will the IMMX options vest?

They vest in 48 equal monthly instalments following the 20-Jun-2025 grant date.

What is Gabriel Morris’s total IMMX share ownership after the filing?

He reports 288,059 direct shares, 294,985 indirect shares, and 340,000 option shares.

Does the Form 4 indicate a sale or purchase of existing shares?

No. The filing only shows an equity award (code "A"); there were no market purchases or sales.

Is the transaction linked to a Rule 10b5-1 trading plan?

The checkbox for a Rule 10b5-1 plan is unchecked, so no such plan is indicated.
Stock IMMX logo
Immix Biopharma Inc

NASDAQ:IMMX

IMMX Rankings

#7299 Ranked by Market Cap
N/A Ranked by Dividends

IMMX Latest News

IMMX Latest SEC Filings

IMMX Stock Data

79.45M
16.62M
40.35%
12.32%
0.82%
Biotechnology
Pharmaceutical Preparations
United States
LOS ANGELES